menu
    • menu
    [{"orgOrder":0,"company":"WraSer Pharmaceuticals","sponsor":"Blue Water Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Levoamlodipine","moa":"Calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"WraSer Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"WraSer Pharmaceuticals \/ Blue Water Vaccines","highestDevelopmentStatusID":"15","companyTruncated":"WraSer Pharmaceuticals \/ Blue Water Vaccines"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Levoamlodipine","moa":"L-type calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Seoul National University Bundang Hospital","sponsor":"Hanlim Pharmaceuticals Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Levoamlodipine","moa":"Voltage-dependent L-type calcium channel subunit alpha-1C; Voltage-dependent L-type calcium channel subunit alpha-1D; Nitric oxide synthase 3; Nitric oxide synthase, inducible","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Seoul National University Bundang Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Bundang Hospital \/ Hanlim Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Seoul National University Bundang Hospital \/ Hanlim Pharmaceutical"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Asan Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Levoamlodipine","moa":"Voltage-dependent L-type calcium channel subunit alpha-1C; Voltage-dependent L-type calcium channel subunit alpha-1D; Nitric oxide synthase 3; Nitric oxide synthase, inducible","graph1":"Undisclosed","graph2":"Phase I","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chong Kun Dang Pharm \/ Asan Medical Center","highestDevelopmentStatusID":"6","companyTruncated":"Chong Kun Dang Pharm \/ Asan Medical Center"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Levoamlodipine","moa":"Voltage-dependent L-type calcium channel subunit alpha-1C; Voltage-dependent L-type calcium channel subunit alpha-1D; Nitric oxide synthase 3; Nitric oxide synthase, inducible","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Neutec Ar-Ge San ve Tic A.?","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TURKEY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Levoamlodipine","moa":"Voltage-dependent L-type calcium channel subunit alpha-1C; Voltage-dependent L-type calcium channel subunit alpha-1D; Nitric oxide synthase 3; Nitric oxide synthase, inducible","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Neutec Ar-Ge San ve Tic A.?","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neutec Ar-Ge San ve Tic A.? \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Neutec Ar-Ge San ve Tic A.? \/ Undisclosed"},{"orgOrder":0,"company":"Conjupro Biotherapeutics","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Levoamlodipine","moa":"Voltage-gated L-type calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Conjupro Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Conjupro Biotherapeutics \/ CSPC Ouyi Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"6","companyTruncated":"Conjupro Biotherapeutics \/ CSPC Ouyi Pharmaceutical Co., Ltd"}]

    Find Clinical Drug Pipeline Developments & Deals for Levoamlodipine

    Menu

    Levoamlodipine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            WraSer Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            WraSer Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levoamlodipine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Blue Water Vaccines

                            Deal Size : $8.5 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment A...

                            Details : Blue Water expands its commercial portfolio by purchasing six FDA-approved assets across multiple indications, including cardiology, otic infections, and pain management. The assets also include Conjupri (levamlodipine), a calcium channel blocker for the...

                            Product Name : Conjupri

                            Product Type : Miscellaneous

                            Upfront Cash : $8.5 million

                            June 14, 2023

                            Lead Product(s) : Levoamlodipine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Blue Water Vaccines

                            Deal Size : $8.5 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Conjupro Biotherapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Conjupro Biotherapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levoamlodipine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : CSPC Ouyi Pharmaceutical Co., Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioavailability of 5 mg of Levamlodipine Maleate Tablets Versus 10 mg of Amlodipine Besylate Tablet in Healthy...

                            Details : Levamlodipine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hypertension.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 05, 2018

                            Lead Product(s) : Levoamlodipine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : CSPC Ouyi Pharmaceutical Co., Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Seoul National University Bundang Hospital

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Seoul National University Bundang Hospital

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levoamlodipine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Hanlim Pharmaceuticals Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            S-amlodipine+Chlorthalidone vs S-amlodipine+Telmisartan in Hypertension

                            Details : S-Amlodipine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Essential Hypertension.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 21, 2017

                            Lead Product(s) : Levoamlodipine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Hanlim Pharmaceuticals Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Neutec Ar-Ge San ve Tic A.?

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Neutec Ar-Ge San ve Tic A.?

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levoamlodipine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of S-amlodipine 2,5 mg and 5 mg in Hypertension Patients

                            Details : S-Amlodipine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypertension.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 31, 2017

                            Lead Product(s) : Levoamlodipine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Chong Kun Dang Pharm

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Chong Kun Dang Pharm

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levoamlodipine

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Asan Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CKD-828 Drug Interaction Study (S-amlodipine)

                            Details : S-Amlodipine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 19, 2011

                            Lead Product(s) : Levoamlodipine

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Asan Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levoamlodipine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Levamlodipine Besylate Compared to Amlodipine Maleate in Patients With Essential Hypert...

                            Details : Levamlodipine Besylate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Essential Hypertension.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 27, 2010

                            Lead Product(s) : Levoamlodipine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Chong Kun Dang Pharm

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Chong Kun Dang Pharm

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levoamlodipine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CKD-828 Primary Hypertension Trial(Dose-selection)

                            Details : S-Amlodipine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hypertension.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 21, 2010

                            Lead Product(s) : Levoamlodipine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth